title: Uterine tumours are a phenotypic manifestation of the hyperparathyroidism-jaw tumour syndrome.
abstract: The hyperparathyroidism-jaw tumour (HPT-JT) syndrome is an autosomal dominant disorder characterized by parathyroid tumours, which are frequently carcinomas, and ossifying jaw fibromas. In addition, some patients may develop renal tumours and cysts. The gene causing HPT-JT, which is referred to as HRPT2 and is located on chromosome 1q31.2, encodes a 531 amino acid protein called PARAFIBROMIN. To date 42 mutations, of which 22 are germline, have been reported and 97% of these are inactivating and consistent with a tumour suppressor role for HRPT2. We have investigated another four HPT-JT families for germline mutations, searched for additional clinical phenotypes, and examined for a genotype-phenotype correlation. Mutations were found in two families. One family had a novel deletional-insertion at codon 669, and the other had a 2 bp insertion at codon 679, which has been reported in four other unrelated patients. These five unrelated patients and their families with the same mutation were not found to develop the same tumours, thereby indicating an absence of a genotype-phenotype correlation. An analysis of 33 HPT-JT kindreds revealed that affected women in 13 HPT-JT families suffered from menorrhagia in their second to fourth decades. This often required hysterectomy, which revealed the presence of uterine tumours. This resulted in a significantly reduced maternal transmission of the disease. Thus, the results of our analysis expand the spectrum of HPT-JT-associated tumours to include uterine tumours, and these may account for the decreased reproductive fitness in females from HPT-JT families.
authors.affiliation: Academic Endocrine Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Headington, Oxford, UK.
authors.forename: K J
authors.initials: KJ
authors.lastname: Bradley
authors.forename: M R
authors.initials: MR
authors.lastname: Hobbs
authors.forename: I D
authors.initials: ID
authors.lastname: Buley
authors.forename: J D
authors.initials: JD
authors.lastname: Carpten
authors.forename: B M
authors.initials: BM
authors.lastname: Cavaco
authors.forename: J E
authors.initials: JE
authors.lastname: Fares
authors.forename: P
authors.initials: P
authors.lastname: Laidler
authors.forename: S
authors.initials: S
authors.lastname: Manek
authors.forename: C M
authors.initials: CM
authors.lastname: Robbins
authors.forename: I S
authors.initials: IS
authors.lastname: Salti
authors.forename: N W
authors.initials: NW
authors.lastname: Thompson
authors.forename: C E
authors.initials: CE
authors.lastname: Jackson
authors.forename: R V
authors.initials: RV
authors.lastname: Thakker
mesh_terms: D000328:Adult; D005192:Family Health; D005260:Female; D005838:Genotype; D006801:Humans; D006961:Hyperparathyroidism / Q000235:genetics* / Q000473:pathology; D007573:Jaw Neoplasms / Q000235:genetics* / Q000473:pathology; D008297:Male; D008595:Menorrhagia / Q000150:complications / Q000473:pathology; D008875:Middle Aged; D009154:Mutation; D009378:Neoplasms, Multiple Primary / Q000235:genetics* / Q000473:pathology; D010641:Phenotype; D011506:Proteins / Q000235:genetics; D013577:Syndrome; D025521:Tumor Suppressor Proteins; D014594:Uterine Neoplasms / Q000235:genetics* / Q000473:pathology
chemical_list: C454900:CDC73 protein, human; D011506:Proteins; D025521:Tumor Suppressor Proteins